BostonGene

The AI engine Fit Assessment

Beta

BostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.

Blurb

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

HQ Location

Waltham (United States)

Founded

2015

Employees

201 - 500

Total funding raised

$200.00M

Last Funding Event

Series B, $150.00M, April 6, 2022

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies